Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later
Objective Examine the relationship between 1‐ and 2‐month weight loss (WL) and 8‐year WL among participants enrolled in a lifestyle intervention. Methods 2,290 Look AHEAD participants (BMI: 35.65 ± 5.93 kg/m2) with type 2 diabetes received an intensive behavioral WL intervention. Results 1‐ and 2‐mo...
Saved in:
| Published in: | Obesity (Silver Spring, Md.) Vol. 23; no. 7; pp. 1353 - 1356 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Blackwell Publishing Ltd
01-07-2015
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Objective
Examine the relationship between 1‐ and 2‐month weight loss (WL) and 8‐year WL among participants enrolled in a lifestyle intervention.
Methods
2,290 Look AHEAD participants (BMI: 35.65 ± 5.93 kg/m2) with type 2 diabetes received an intensive behavioral WL intervention.
Results
1‐ and 2‐month WL were associated with yearly WL through Year 8 (P's < 0.0001). At Month 1, participants losing 2‐4% and >4% had 1.62 (95% CI: 1.32, 1.98) and 2.79 (95% CI: 2.21, 3.52) times higher odds of achieving ≥5% WL at Year 4 and 1.28 (95% CI: 1.05,1.58) and 1.77 (95% CI: 1.40, 2.24) times higher odds of achieving ≥5% WL at Year 8, compared to those losing <2% initially. At Month 2, 3‐6% WL resulted in greater odds of achieving ≥5% WL at Year 4 (OR = 1.85; CI: 1.48, 2.32), and >6% WL resulted in the greatest odds of achieving ≥5% WL at Year 4 (OR = 3.85; CI: 3.05, 4.88) and Year 8 (OR = 2.28; CI: 1.81, 2.89), compared to those losing <3%. Differences in adherence between WL categories were observed as early as Month 2.
Conclusions
1‐ and 2‐month WL was associated with 8‐year WL. Future studies should examine whether alternative treatment strategies can be employed to improve treatment outcomes among those with low initial WL. |
|---|---|
| Bibliography: | Dr. Cheskin is the Chair of the Scientific Advisory Board for Medifast, Inc. The remaining authors have no conflicts of interest to disclose. See online Supporting Information for full list of trial personnel. RN and PH had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. RJ, XP, DSW, RW, and LC contributed to the study design, JN collected the data and assisted with the intervention, PH and RN performed the data analyses, and JU wrote the manuscript. All authors contributed to the discussion and interpretation of the data and reviewed and edited the manuscript. Disclosure Funding agencies This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health (NIH): DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (I.H.S.) provided personnel, medical oversight, and use of facilities. The opinions expressed in this paper are those of the authors and do not necessarily reflect the views of the I.H.S. or other funding sources. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (M01RR000056 44) and NIH grant (DK 046204); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346). The following organizations have committed to make major contributions to Look AHEAD: Federal Express; Health Management Resources; Johnson & Johnson, LifeScan Inc.; Optifast‐Novartis Nutrition; Roche Pharmaceuticals; Ross Product Division of Abbott Laboratories; Slim‐Fast Foods Company; and Unilever. The National Institute of Diabetes and Digestive and Kidney Diseases participated in the design and conduct of the study but did not participate in the collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The decision to publish was made by the Look AHEAD Steering Committee, with no restrictions imposed by the sponsor. Author contributions ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
| ISSN: | 1930-7381 1930-739X |
| DOI: | 10.1002/oby.21112 |